185 related articles for article (PubMed ID: 35693379)
1. Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
Fan L; Zhang Y; Maguire P; Muston D; Monberg M; Earla JR; Mihai A; Gulati P
J Mark Access Health Policy; 2022; 10(1):2078474. PubMed ID: 35693379
[TBL] [Abstract][Full Text] [Related]
2. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
5. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
6. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis.
Dai MF; Wang X; Xin WX; Kong SS; Xu WB; Ding HY; Fang L
Expert Rev Anticancer Ther; 2024 Jul; 24(7):613-622. PubMed ID: 38761169
[TBL] [Abstract][Full Text] [Related]
7. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
Ding H; He C; Tong Y; Fang Q; Mi X; Chen L; Xin W; Fang L
PLoS One; 2022; 17(12):e0279286. PubMed ID: 36520958
[TBL] [Abstract][Full Text] [Related]
10. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
[TBL] [Abstract][Full Text] [Related]
11. Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials.
Bowling GC; Swargaloganathan P; Heintz C; Madan RA; Eldhose B; Dobi A; Chesnut GT
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835597
[TBL] [Abstract][Full Text] [Related]
12. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.
Zhang D; Li S; Zhang X; Peng J; Zhang S
Front Oncol; 2022; 12():955124. PubMed ID: 36059631
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
Stemmer A; Shafran I; Stemmer SM; Tsoref D
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081005
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis.
Luo J; Ou S; Wei H; Qin X; Jiang Q
Front Oncol; 2022; 12():815265. PubMed ID: 35756600
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
16. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
17. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
18. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.
Rimel BJ; Chase DM; Perhanidis J; Ghazarian AA; Du EX; Wang T; Song J; Golembesky AK; Hurteau JA; Kalilani L; Salani R; Monk BJ
Gynecol Oncol Rep; 2024 Feb; 51():101332. PubMed ID: 38362364
[TBL] [Abstract][Full Text] [Related]
20. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
